INTRODUCTION {#s1}
============

With the fast developments of computer-aided drug design (CADD) \[[@R1]--[@R5]\], currently a number of drug design approaches are developed, and several computer software packs \[[@R6], [@R7]\] are available that can speed up the discovery of new chemical and biological drugs in more efficient and economical procedure. However, so far we still have no perfect theories, ideal technologies, and faultless software tools that can guarantee complete success of the designed drugs due to the complicity of the interactions between medicinal drugs and their biological targets \[[@R8], [@R9]\]. The factors and parameters that may affect the bioactivities of drugs are not only from the structure of drug itself, but also from its biological target, coenzymes, and interaction environment \[[@R10], [@R11]\].

Principal component analysis (PCA) \[[@R12]--[@R14]\] is a useful tool that has been widely used in chemistry, biology, environment, and many fields of social science. The PCA approach has also been used in drug design for many years. Traditionally PCA is a single level and one direction prediction and analysis technique, described as the following equation$$\sum\limits_{k = 1}^{K}{\left( {a_{k}x_{i,k}} \right) = w_{i}}$$where $\left\{ x_{i,k} \right\}$ are the physicochemical parameters of the *i*-th molecule, $\left\{ a_{k} \right\}$ are the coefficients of molecular parameters, and *w*~*i*~ is bioactivity of the *i*-th molecule \[[@R15], [@R16]\]. The bioactivity *w*~*i*~ could be logarithm of IC~50,*i*~ (pIC~50,*i*~=-logIC~50,*i*~), or binding free energy Δ*G*°~*i*~ between drug and receptor.

After the coefficients $\left\{ a_{k} \right\}$ of parameters are solved from the linear equations Eq.[1](#eq001){ref-type="disp-formula"} in a training set of drug candidates, the parameter coefficients $\left\{ a_{k} \right\}$ can be used to predict the bioactivities of the designed or newly synthesized drug compounds,$$w_{i}^{\text{pred}} = {\sum\limits_{k = 1}^{K}\left( {a_{k}x_{i,k}} \right)}$$where *K* is the total number of molecular parameters. Currently hundreds even thousands of molecular parameters are available for drug design \[[@R17], [@R18]\]. However for certain drug-receptor interaction system, these parameters are not equally important; actually too many parameters may cause the over correlation problem \[[@R19], [@R20]\]. In PCA technique only the principle components are selected to describe the bioactivities of drug molecules, and to predict the bioactivities of drug candidates.

In the present study, an improved principal component analysis method, the so-called two-level principal component analysis (2L-PCA), is proposed to deal with the extreme complexity and huge amount of parameters in drug design and discovery. In the 2L-PCA predictor, the 1^st^ level is to deal with the physicochemical properties of drug molecules, and the 2^nd^ level is to deal with the fragments of molecular structures. The proposed two-level model can not only significantly enhance the prediction power, but also yield more useful information for in-depth analysis.

According to Chou's 5-step rule \[[@R21]\] that has been widely used by many investigators (see, e.g., \[[@R22]--[@R37]\]), to develop a really useful statistical predictor, one should consider the following five procedures: (1) benchmark dataset; (2) sample representation; (3) operation algorithm; (4) cross validation; (5) web-server. Below, let us describe how to deal with them one-by-one. However, to comply with the Journal's rubric style, they are not exactly following the aforementioned order.

RESULTS AND DISCUSSION {#s2}
======================

As an example to show the advantage of 2L-PCA, we applied it for predicting the binding affinity of epitope-peptides with class I MHC molecules HLA-A\*0201 \[[@R38], [@R39]\]. HLA-A\*0201 is one of the most frequent class I alleles found in many different species and populations, which plays a critical role for antigen presentation in both viral antigens \[[@R40]\] and tumor antigens from a variety of cancers \[[@R41]--[@R44]\], and is expressed in approximately 50% of Caucasians population \[[@R45]\].

The epitope-peptides consist of nine amino acids \[[@R38], [@R39]\]. In the 2L-PCA study for the epitope-peptides, the nine side chains of the nine amino acids are the nine fragments. Eight physicochemical properties are used as the descriptors of the 20 natural amino acids. Four of them are the HMLP parameters \[[@R15], [@R16]\], describing the lipophilic character, hydrophilic character, surface area with lipophilic potential, and surface area with hydrophilic potential, respectively. The fifth property is the volume of amino acid side chains. The remaining three properties are the secondary structural potency indices of amino acids: the α-potency, β-potency, and coil-potency \[[@R46]\]. Listed in Table [1](#T1){ref-type="table"} are the eight physicochemical parameters of 20 amino acids used in this study.

###### Eight physicochemical parameters^a^ of 20 natural amino acid side chains

  A.A.      Lip      Hyd       S~L~ (Å^2^)   S~H~ (Å^2^)   P~α~   P~β~   P~c~   V(Å^3^)
  --------- -------- --------- ------------- ------------- ------ ------ ------ ---------
  Leu (L)   1.2906   0.0000    84.5476       0.0000        1.21   1.30   0.68   166.7
  Ile (I)   1.1046   0.0000    88.6055       0.0000        1.08   1.60   0.66   166.7
  Val (V)   0.5324   0.0000    77.8108       0.0000        1.06   1.70   0.62   140.0
  Phe (F)   0.4412   -0.1195   105.7054      11.2472       1.13   1.38   0.71   189.9
  Met (M)   1.0768   -0.3068   70.3631       23.2299       1.45   1.05   0.58   162.9
  Trp (W)   0.8364   -0.4310   133.6980      14.8820       1.08   1.37   0.75   227.8
  Ala (A)   0.1744   0.0000    34.7760       0.0000        1.42   0.83   0.70   88.6
  Cys (C)   0.2479   -0.2402   23.5563       30.4540       0.70   1.19   1.18   108.5
  Gly (G)   0.0208   0.0000    3.7616        0.0000        0.57   0.75   1.50   60.1
  Tyr (Y)   0.4534   -0.5896   80.9646       42.7160       0.69   1.47   1.06   193.6
  Thr (T)   1.4265   -0.4369   46.7285       16.0490       0.83   1.19   1.07   116.1
  Ser (S)   0.2346   -0.6040   26.0681       15.9613       0.77   0.75   1.32   89.0
  His (H)   0.8124   -0.7766   82.1701       13.8631       1.00   0.87   1.06   153.2
  Gln (Q)   1.0036   -0.7211   70.0876       17.8662       1.11   1.10   0.86   143.9
  Lys (K)   1.4600   -0.6229   97.7144       8.0786        1.16   0.74   0.98   168.7
  Asn (N)   0.6396   -0.7211   50.5075       17.7804       0.67   0.89   1.35   117.7
  Glu (E)   1.0315   -0.9298   57.1582       25.5726       1.51   0.37   0.84   138.4
  Asp (D)   0.6058   -0.9298   37.4173       25.2736       1.01   0.54   1.20   111.1
  Arg (R)   1.2424   -1.4797   90.8008       35.3095       0.98   0.93   1.04   173.4
  Pro (P)   0.3226   0.0000    69.2297       0.0000        0.57   0.55   1.59   122.7

Lip: lipophilic index; Hyd: hydrophilic index; S~L~: lipophilic surface area; S~H~: hydrophilic surface area; P~α~: potency of α-helix; P~β~: potency of β-band; P~**c**~: potency of loop; V: volume of side chains.

In this study the HMLP parameters were used to describe the lipophilicity and hydrophilicity of molecular fragments. In peptides the HMLP parameters of the 20 natural amino acid side chains are available from literatures. However, the HMLP parameters of common chemical molecular fragments have to be derived using complicated calculations. In such cases other hydrophobic parameters can be used, e.g., the atom-based hydrophobic parameters in \[[@R47]\].

To reduce computational time, the cross validation in this study was performed via the independent dataset test \[[@R48]\], as described as follows. The sequences and experimental binding affinities of the 90 peptides were used as the training dataset to train the model, while those of the 40 peptides taken from \[[@R49]\] as the independent dataset to test the model. Actually, such 40 peptides had also been compiled in a series of publications \[[@R41], [@R42], [@R50]--[@R55]\]. The logarithms (pIC~50~) of IC~50~ were used as the bioactivity, because they are related to the changes in the free binding energy \[[@R55], [@R56]\]. Listed in Table [2](#T2){ref-type="table"} are the sequences and the experimental pIC~50~ of the peptides used in the training set. The binding strength of the 90 training peptides and 40 testing peptides covers the low, intermediate, and high affinity. The following two criteria were applied in the choice of the testing peptides: **(1)** the range of binding affinities in the testing dataset should not exceed the range of affinities in the training set; **(2)** the amino acid at each position in the testing dataset should also be present at that position in the training set of peptides. These two conditions make the 130 peptides to be the ideal benchmark dataset for 2L-PCA method.

###### Amino acid sequences and experimental and predicted bioactivities of 90 MHC-I peptides in the training set

  -------------------------------------------------------------------------------------------------
  No.   Peptide\    Expt\     Pred\     pIC~50~\   No.   Peptide\    Expt\     Pred\     pIC~50~\
        sequence    pIC~50~   pIC~50~   Diff             sequence    pIC~50~   pIC~50~   Diff
  ----- ----------- --------- --------- ---------- ----- ----------- --------- --------- ----------
  1     VALVGLFVL   5.148     5.7543    -0.6063    46    VVMGTLVAL   7.174     7.3163    -0.1423

  2     GTLVALVGL   5.342     5.9368    -0.5948    47    YLEPGPVTI   7.187     7.1654    0.0216

  3     LQTTIHDII   5.501     5.8143    -0.3133    48    GLSRYVARL   7.248     7.4620    -0.2131

  4     SLHVGTQCA   5.842     6.1580    -0.3160    49    LLAQFTSAI   7.301     7.4302    -0.1292

  5     ALPYWNFAT   5.869     6.6416    -0.7726    50    VLLDYQGML   7.328     7.5911    -0.2631

  6     SLNFMGYVI   5.881     5.9560    -0.0750    51    YLEPGPVTV   7.342     7.4078    -0.0658

  7     NLQSLTNLL   6.000     6.6992    -0.6992    52    ILSPFMPLL   7.3470    7.1400    0.2070

  8     FVTWHRYHL   6.025     5.7230    0.3020     53    YLSPGPVTA   7.383     7.5610    -0.1780

  9     DPKVKQWPL   6.176     5.7407    0.4354     54    IIDQVPFSV   7.398     7.6528    -0.2548

  10    ITSQVPFSV   6.196     6.5888    -0.3928    55    SVYDFFVWL   7.444     7.3654    0.0786

  11    ALAKAAAAI   6.211     6.2433    -0.0323    56    ITWQVPFSV   7.463     7.4417    0.0213

  12    GLGQVPLIV   6.301     6.5651    -0.2641    57    ITYQVPFSV   7.480     7.6613    -0.1813

  13    MLDLQPETT   6.335     6.8570    -0.5220    58    GLYSSTVPV   7.481     7.6303    -0.1493

  14    LLSSNLSWL   6.342     6.3502    -0.0082    59    VMGTLVALV   7.553     7.2369    0.3161

  15    GLACHQLCA   6.380     6.0594    0.3206     60    LLLCLIFLL   7.585     7.1406    0.4444

  16    LIGNESFAL   6.415     7.0559    -0.6409    61    SLDDYNHLV   7.585     7.1764    0.4086

  17    ALAKAAAAV   6.419     6.4857    -0.0667    62    VLIQRNPQL   7.644     6.9473    0.6967

  18    LLAVGATKV   6.477     6.5115    -0.0344    63    SLYADSPSV   7.658     7.7106    -0.0526

  19    ALAKAAAAL   6.511     6.2262    0.2848     64    ILSQVPFSV   7.699     7.6472    0.0518

  20    WILRGTSFV   6.556     6.9084    -0.3524    65    IMDQVPFSV   7.719     8.0305    -0.3115

  21    IISCTCPTV   6.580     6.6649    -0.0849    66    QLFEDNYAL   7.764     7.4713    0.2927

  22    FLGGTPVCL   6.623     6.8756    -0.2526    67    ALMDKSLHV   7.770     7.5250    0.2450

  23    ALIHHNTHL   6.623     6.7908    -0.1677    68    YAIDLPVSV   7.796     7.6075    0.1885

  24    NLSWLSLDV   6.639     6.0466    0.5924     69    FVWLHYYSV   7.824     8.1149    -0.2909

  25    YMIMVKCWM   6.663     6.6427    0.02035    70    MLGTHTMEV   7.845     7.3180    0.5270

  26    VLQAGFFLL   6.682     7.0412    -0.3592    71    LLFGYPVYV   7.886     8.0253    -0.1393

  27    GTLGIVCPI   6.714     6.5233    0.1907     72    ILKEPVHGV   7.921     7.5915    0.3295

  28    VILGVLLLI   6.785     7.4728    -0.6878    73    YLMPGPVTV   7.932     7.9139    0.0181

  29    VTWHRYHLL   6.793     6.5597    0.2333     74    WLDQVPFSV   7.939     7.9514    -0.0124

  30    PLLPIFFCL   6.796     7.5217    -0.7257    75    KTWGQYWQV   7.955     7.6934    0.2616

  31    TLGIVCPIC   6.815     5.9499    0.8651     76    ALMPLYACI   8.000     7.4383    0.5617

  32    CLTSTVQLV   6.832     7.1061    -0.2741    77    YLAPGPVTA   8.032     7.6408    0.3912

  33    ILLLCLIFL   6.845     6.7815    0.0635     78    YLYPGPVTV   8.051     8.3112    -0.2602

  34    FAFRDLCIV   6.886     6.6689    0.2171     79    LLMGTLGIV   8.097     7.6769    0.4201

  35    FLEPGPVTA   6.898     7.4940    -0.5960    80    YLWPGPVTV   8.125     8.0916    0.0334

  36    ALAKAAAAA   6.947     6.8081    0.1389     81    FLLTRILTI   8.149     7.8796    0.2694

  37    LMAVVLASL   6.954     7.4908    -0.5368    82    GLLGWSPQA   8.237     8.2184    0.0185

  38    YVITTQHWL   6.983     6.3410    0.6420     83    ILYQVPFSV   8.310     8.7197    -0.4097

  39    LLCLIFLLV   6.996     7.5015    -0.5055    84    GILTVILGV   8.347     7.8414    0.5056

  40    ITAQVPFSV   7.020     6.6685    0.3515     85    NMVPFFPPV   8.398     8.0854    0.3126

  41    YLEPGPVTL   7.058     7.1483    -0.0903    86    ILDQVPFSV   8.481     7.6904    0.7906

  42    YTDQVPFSV   7.066     7.0742    -0.0082    87    YLFPGPVTA   8.495     8.3473    0.1477

  43    NLYVSLLLL   7.114     6.9769    0.1371     88    YLDQVPFSV   8.638     8.1326    0.5054

  44    ILHNGAYSL   7.127     7.3493    -0.2223    89    ILFQVPFSV   8.699     8.4335    0.2655

  45    SIISAVVGI   7.159     7.3048    -0.1458    90    ILWQVPFSV   8.770     8.5002    0.2698
  -------------------------------------------------------------------------------------------------

Statistical indices:

R=0.887132 R^2^= 0.787003 RES=0.366873 SEE=0.038672.

The iterative 2L-PCA technique described in Method section is used for the binding affinity study of peptides based on the sequences and experimental data listed in Table [2](#T2){ref-type="table"}. The initial coefficient values $\left\{ b_{l}^{(0)} \right\}$ of fragment parameters were assigned to 1, implying that all fragment parameters are equally important. Shown in Figure [1](#F1){ref-type="fig"} are the curves of correlation coefficients *R vs* iterations , where the curve *R*~*a*~ is for the iteration of coefficients $\left\{ a_{k} \right\}$, and the curve *R*~*b*~ is for the iterations of coefficients $\left\{ b_{l} \right\}$. The average fitting error *Q* between the calculated bioactivities and the experimental bioactivities of peptides are shown in Figure [2](#F2){ref-type="fig"}, where *Q*~*a*~ is for $\left\{ a_{k} \right\}$ iteration and *Q*~*b*~ for $\left\{ b_{l} \right\}$ iteration. It has been observed that, after 10 to 12 iterations, the iterative result converged smoothly. The converged prediction coefficient sets $\left\{ a_{k}^{(n)} \right\}$ and $\left\{ b_{l}^{(n)} \right\}$ are given in Table [3](#T3){ref-type="table"}. In the iterative solution precedure the correlation coefficien increases from the first value R~A~^(1)^=0.4167 to the converged value R~A~^(98)^=0.8871, and the prediction residue decreases from the first value Q~A~^(1)^=0.7223 to the converged value Q~A~^(98)^=0.0387.

![The correlation coefficients between experimental and predicted bioactivities increase with the iterations\
*R*~*a*~ is the correlation coefficient in the iterative procedure for $\left\{ a_{k}^{(n)} \right\}$ of the physicochemical properties, and *R*~*b*~ is the correlation coefficient in the iterative procedure for $\left\{ b_{l}^{(n)} \right\}$ of the molecular fragments.](oncotarget-08-70564-g001){#F1}

![The residue between predicted bioactivities and experimental bioactivities in the iterative procedure\
The *Q* is the average square root of the summation of squared differences between predicted bioactivities and experimental bioactivities. *Q*~*a*~ is for $\left\{ a_{k}^{(n)} \right\}$ iteration and *Q*~*b*~ is for $\left\{ b_{l}^{(n)} \right\}$ iteration.](oncotarget-08-70564-g002){#F2}

###### Prediction coefficients of eight physicochemical properties and nine residue positions obtained from the training set of MHC-I peptides

  No.   Property   Coefficient   No.   Position   Coefficient
  ----- ---------- ------------- ----- ---------- -------------
  1     Lip        -0.02445      1     R1         2.53268
  2     Hyd        0.19258       2     R2         8.36712
  3     S^L^       -0.00212      3     R3         3.06856
  4     S^H^       0.00348       4     R4         -4.89559
  5     P~α~       0.15367       5     R5         3.12686
  6     P~β~       0.07823       6     R6         2.45367
  7     P~c~       0.19764       7     R7         1.24669
  8     Vol        0.00366       8     R8         -3.50416
  \--   \--        \--           9     R9         -3.79249

The predicted pIC~50~ of the 40 queried peptides in the testing set are given in Table [4](#T4){ref-type="table"}, which were predicted using the coefficients $\left\{ a_{k}^{(n)} \right\}$ of properties and $\left\{ b_{l}^{(n)} \right\}$ of fragments based on the eight physicochemical parameters and the nine fragments (amino acid side chains). The diversity of the peptides in the training set is very important for the prediction power of TLPC, especially for the residue positions at which we want to make prediction. It is expected that, with more experimental data available, the predictive power of 2L-PCA will be further improved. Actually, 30 prediction servers for human MHC-I peptide molecules were evaluated in a review article \[[@R57]\]. Among the 30 existing servers, 16 were ranked as the first class that provided the most accurate prediction results for MHC-I peptide molecules with the correlation coefficients ranging from r = 0.55 to r = 0.87. It has been shown in this study that the prediction correlation coefficient yielded by our 2L-PCA method is r = 0.868, being ranked around the very top of the first class.

###### Amino acid sequences and experimental and predicted bioactivities of 40 MHC-I peptides in the testing set

  -----------------------------------------------------------------------------------------------
  No   Sequence    Expt\     Pred\     pIC~50~\   No   Sequence    Expt\     Pred\     pIC~50~\
                   pIC~50~   pIC~50~   Diff                        pIC~50~   pIC~50~   Diff
  ---- ----------- --------- --------- ---------- ---- ----------- --------- --------- ----------
  1    LLGCAANWI   5.301     5.1708    0.1302     21   ITFQVPFSV   7.179     7.3750    -0.1960

  2    SAANDPIFV   5.342     4.8592    0.4828     22   FTDQVPFSV   7.212     6.8379    0.3741

  3    TTAEEAAGI   5.380     5.4678    -0.0878    23   RLMKQDFSV   7.342     7.5681    -0.2261

  4    LTVILGVLL   5.580     5.3216    0.2584     24   KLHLYSHPI   7.352     6.6450    0.7070

  5    HLLVGSSGL   5.792     6.4811    -0.6891    25   ITMQVPFSV   7.398     7.2641    0.1340

  6    GIGILTVIL   6.000     5.7321    0.2679     26   KIFGSLAFL   7.478     6.7818    0.6962

  7    TVILGVLLL   6.072     5.4662    0.6058     27   ALVGLFVLL   7.585     7.3852    0.1998

  8    WTDQVPFSV   6.145     6.8930    -0.7480    28   YLSPGPVTV   7.642     7.2387    0.4033

  9    AIAKAAAAV   6.176     6.4480    -0.2720    29   GLYSSTVPV   7.699     7.6303    0.0687

  10   ILTVILGVL   6.419     7.0160    -0.5970    30   YLYPGPVTA   7.772     8.6335    -0.8615

  11   AVAKAAAAV   6.495     5.9131    0.5819     31   YLAPGPVTV   7.818     7.3184    0.4996

  12   ILDEAYVMA   6.623     7.4445    -0.8215    32   VVLGVVFGI   7.845     7.4509    0.3941

  13   LLWFHISCL   6.682     6.3594    0.3226     33   MMWYWGPSL   7.921     7.4007    0.5203

  14   TLDSQVMSL   6.793     7.2566    -0.4636    34   ILAQVPFSV   7.939     7.7270    0.2120

  15   HLYQGCQVV   6.832     7.6799    -0.8479    35   FLLSLGIHL   8.053     8.1578    -0.1048

  16   QLFHLCLII   6.886     7.6475    -0.7615    36   ILMQVPFSV   8.125     8.3225    -0.1975

  17   ITDQVPFSV   6.947     6.6320    0.3150     37   YLFPGPVTV   8.237     8.0249    0.2121

  18   ALCRWGLLL   7.000     7.2766    -0.2766    38   YLMPGPVTA   8.367     8.2363    0.1307

  19   NLGNLNVSI   7.119     7.0974    0.02160    39   YLWPGPVTA   8.495     8.4140    0.0810

  20   HLYSHPIIL   7.131     7.5663    -0.4353    40   FLDQVPFSV   8.658     7.8964    0.7616
  -----------------------------------------------------------------------------------------------

Statistical indices:

R=0.867872 R^2^= 0.753202 RES=0.469728 SEE=0.074271.

2L-PCA neither needs knowing the exact comformations of the peptides nor needs aligning the peptides according to a template. The two steps are necessary but quite difficult for CoMFA \[[@R58], [@R59]\] and CoMSIA \[[@R60], [@R61]\] owing to that there are numerous possible conformations for peptides and that the experimental crystal structure for serving as a template is often not available. 2L-PCA method provides an alternate way for design of the chemical drugs and peptide drugs.

The eigenvalues and contributions of physicochemical properties and amino acid positions in peptides are summarized in Table [5](#T5){ref-type="table"} and shown in Figure [3](#F3){ref-type="fig"}. In Table [5](#T5){ref-type="table"} the eigenvalues are normalized. The eigenvalue portion of the first three property eigenvectors is almost 100%, and the eigenvalue portion of the first eigenvector alone is larger than 99%. Most contributions are made by the three properties: side chain volume (Vol), lipophilic surface area (S^L^), and hydrophilic surface area (S^H^), as shown in Figure [3b](#F3){ref-type="fig"} and Table [5](#T5){ref-type="table"}. The contributions of other 5 properties seem very small. The eigenvalue of the first peptide position eigenvector is larger than 98%. In Table [5](#T5){ref-type="table"} the contributions of the nine amino acid positions are different. However the differences are not big, implying that all positions are almost equally important. The detailed computation results are given in [Supplementary Information 1](#SD2){ref-type="supplementary-material"}.

###### Eigenvalues and contributions of physicochemical properties and amino acid positions in training set of peptides

  Physicochemical properties   Positions (fragments)                                              
  ---------------------------- ----------------------- ------ --------- --- --------- ----------- ---------
  1                            0.99118                 Lip    0.00004   1   0.98873   Residue-1   0.12126
  2                            0.00641                 Hyd    0.00000   2   0.00300   Residue-2   0.12043
  3                            0.00240                 S^L^   0.20595   3   0.00249   Residue-3   0.1130
  4                            0.00005                 S^H^   0.00534   4   0.00213   Residue-4   0.09871
  5                            0.00004                 P~α~   0.00004   5   0.00106   Residue-5   0.1046
  6                            0.00003                 P~β~   0.00005   6   0.00094   Residue-6   0.10804
  7                            0.00002                 P~c~   0.00002   7   0.0007    Residue-7   0.11931
  8                            0.00001                 Vol    0.78857   8   0.00058   Residue-8   0.10186
  \--                          \--                     \--    \--       9   0.00037   Residue-9   0.11278

^a^ Eigenvalues are normalized.

^b^ The positions of peptides are equal to the fragments of molecules.

![Eigenvalues and contributions of properties and peptide positions\
**(a)** The eigenvalues of property eigenvectors. **(b)** The contributions of properties to the eigenvalues. The volumes (Vol) and hydrophobic surface areas (S~L~) of amino acid side chains make the largest contributions. **(c)** The eigenvalues of peptide position eigenvectors. **(d)** The contributions of peptide positions to the eigenvalues. The contributions of all nine amino acid positions are almost equally important.](oncotarget-08-70564-g003){#F3}

We are often facing two kinds of challenges in theoretical prediction for drug design: one is over-correlation problem, and the other is lack of information and explanation for the predicted results. The over-correlation problem is caused by large amount of parameters used in the prediction model, which may yield quite good correlation results in self-consistency test \[[@R62], [@R63]\], but very poor predicted results in independent dataset test owing to the high dimensional disaster \[[@R19]\] or "curse of dimensionality" problem. To solve this problem, the pseudo amino acid composition (PseAAC) was introduced \[[@R64]\]. Ever since then, the concept of PseAAC or the general PseAAC \[[@R21]\] has been widely used in drug development and biomedicine \[[@R65], [@R66]\] and nearly all the areas of computational proteomics (see, e.g., \[[@R67]\] as well as a long list of references cited in \[[@R68], [@R69]\]). Actually, the physicochemical properties used here can be regarded as some optimal pseudo components \[[@R70]\]. It is through such a PseAAC approach to remove the trivial parameters (or reduce the feature vector's dimension) and grasp the key ones. Besides, the traditional prediction methods fail to provide a good explanation for the predicted results; i.e., how do the physicochemical properties and the structural changes affect the bioactivities? In contrast to that, the proposed "2L-PCA" method can provide more information about the impact of the physicochemical properties and molecular fragments to the bioactivities of drug candidates.

MATERIALS AND METHODS {#s3}
=====================

In practical drug design and development, usually the basic structure of drug candidates keep constant, only small modifications are made on several fragments. The structure parameters of the entire molecules cannot clearly describe the detailed characters of the small changes at individual fragments or substitutes. In the 2L-PCA model the molecular structures are separated into several fragments, and are described by a set of fragment parameters. An example of molecular structure and its fragments is shown in Figure [4A](#F4){ref-type="fig"}. The idea of molecular fragments also can be applied to the peptide drugs, in which each side chain of an amino acid is a fragment, as shown in Figure [4B](#F4){ref-type="fig"}.

![Illustration of molecular fragments\
**(A)** The structural fragments in neuraminidase (NA) of influenza virus A inhibitors. The molecular structure is divided into 4 fragments according to the substitutes being investigated. The fragments F~1~, F~2~ and F~3~ are three substituent groups, and the fragment F~4~ is the remaining part of the molecular parent. **(B)** In short peptides each side chain of amino acid residue is a fragment.](oncotarget-08-70564-g004){#F4}

General 3D equation of 2L-PCA {#s3_1}
-----------------------------

In the 2L-PCA prediction model the bioactivity *w*~*i*~ of molecule *i* is the summation of contributions Δ*g*~*i,l*~ from all molecular fragments; i.e.,$$\sum\limits_{l = 1}^{L}{b_{l}{\Delta g}_{i,l} = w_{i}}$$where Δ*g*~*i,l*~ is the contribution of fragment *l* to the bioactivity *w*~*i*~ of molecule *i*, *b*~*l*~ is the prediction coefficient of fragment *l*, and *L* is the total number of molecular fragments. The contribution Δ*g*~*i,l*~ of fragment *l* is the summation of the contributions from all physicochemical properties of fragment *l*, namely$${\Delta g}_{i,l} = {\sum\limits_{k = 1}^{K}{a_{k}x_{i,l,k}}}$$where *x*~*i,l,k*~ is the physicochemical property *k* of fragment *l* in molecule *i*, *a*~*k*~ is the prediction coefficient of physicochemical property *k*, and *K* is the total number of physicochemical properties.

Inserting the Eq.[4](#eq004){ref-type="disp-formula"} into Eq.[3](#eq003){ref-type="disp-formula"} we get the general equation of 2L-PCA prediction model as given by$$\begin{matrix}
{\sum\limits_{l = 1}^{L}{b_{l}\left( {\sum\limits_{k = 1}^{K}{a_{k}X_{i,l,k}}} \right) = w_{i}}} \\
\left( i = 1,2\operatorname{\ldots\ldots},N \right) \\
\end{matrix}$$where *N* is the total number of molecular samples. Eq.[5](#eq005){ref-type="disp-formula"} can be expressed in vector and matrix form as given below$$\mathbf{X}_{N,L,K}\mathbf{B}_{L}\mathbf{A}_{K} = \mathbf{W}_{N}$$where **X**~N,L,K~ is the three dimensional (3D) data matrix of molecular parameters, **W**~N~ is the bioactivity column vector of molecular samples, **B**~L~ is the coefficient vector of fragments, and **A**~K~ is the coefficient vector of physicochemical properties.

2D equations of properties and fragments {#s3_2}
----------------------------------------

The general three-dimensional 2L-PCA equation of Eq.[6](#eq006){ref-type="disp-formula"} can be reduced to two 2D equations with the following algebra operations,$$\mathbf{X}_{N,L,K}\mathbf{A}_{K} = \mathbf{H}_{N,L}$$where **H**~N,L~ is the 2D data matrix of molecular fragments. Substituting **H**~N,L~ into Eq.[6](#eq006){ref-type="disp-formula"}, we obtain the following fragment 2D equation$$\mathbf{H}_{N,L}\mathbf{B}_{L} = \mathbf{W}_{N}$$

Likewise, the property 2D equation can also be expressed as$$\mathbf{X}_{N,L,K}\mathbf{B}_{L} = \mathbf{F}_{N,K}$$and$$\mathbf{F}_{N,K}\mathbf{A}_{K} = \mathbf{W}_{N}$$where **F**~N,K~ is the 2D data matrix of physicochemical properties.

Algebra solutions of property and fragment 2D equations {#s3_3}
-------------------------------------------------------

The fragment 2D equation Eq.[8](#eq008){ref-type="disp-formula"} and the property 2D equation Eq.[10](#eq010){ref-type="disp-formula"} can be solved using the standard algebra method. Both sides of the fragment 2D equation of Eq.[8](#eq008){ref-type="disp-formula"} are multiplied with the transposed matrix **H**^t^~N,L~ from left, it follows that$$\mathbf{H}_{N,L}^{t}\mathbf{H}_{N,L} = \mathbf{U}_{L,L}$$and$$\mathbf{H}_{N,L}^{t}\mathbf{W}_{N} = \mathbf{S}_{L}$$

Thus, we get the following symmetrically square matrix equation of fragments$$\mathbf{U}_{L,L}\mathbf{B}_{L} = \mathbf{S}_{L}$$

Since the fragment square matrix equation of Eq.[13](#eq013){ref-type="disp-formula"} is multiplied by its inverse matrix **U**^-1^~L,L~, the prediction coefficients **B**~L~ for the fragments are obtained, as given below$$\mathbf{B}_{L} = \mathbf{U}_{L,L}^{- 1}\mathbf{S}_{L}$$where the inverse matrix **U**^-1^~L,L~ can be obtained by solving the eigen equation \[[@R71]\] \[[@R48]\] of **U**~L,L~, namely the equation$$\mathbf{U}_{L,L}\mathbf{\Psi}_{L,L} = \mathbf{\alpha}_{L,L}\mathbf{\Psi}_{L,L}$$meaning$$\mathbf{U}_{L,L}^{- 1} = \frac{1}{\alpha_{L}}\mathbf{\Psi}_{L,L}$$where **Ψ**~L,L~ is the eigenvectors and α~L~ is the eigenvalues of fragment square matrix **U**~L,L~\[[@R72], [@R73]\].

Similarly, left-multiplying both sides of property 2D equation of Eq.[10](#eq010){ref-type="disp-formula"} with **F**^t^~N,K~, we have$$\mathbf{F}_{N,K}^{t}\mathbf{F}_{N,K} = \mathbf{V}_{K,K}$$and$$\mathbf{F}_{N,K}^{t}\mathbf{W}_{N} = \mathbf{T}_{K}$$

From Eqs.[17](#eq017){ref-type="disp-formula"}-[18](#eq018){ref-type="disp-formula"}, we get the following square matrix equation of properties$$\mathbf{V}_{K,K}\mathbf{A}_{K} = \mathbf{T}_{K}$$

Multiplying Equation Eq.[19](#eq019){ref-type="disp-formula"} with the inverse matrix **V**^-1^~K,K~, will give the solution of property prediction coefficients **A**~K~; i.e.$$\mathbf{A}_{K}\mathbf{=}\mathbf{V}_{K,K}^{\mathbf{-}1}\mathbf{T}_{K}$$

Thus, the inverse matrix **V**^-1^~K,K~ is obtained by solving the eigen equation of property square matrix **V**~K,K~:$$\mathbf{V}_{K,K}\mathbf{\Phi}_{K,K}\mathbf{=}\mathbf{\beta}_{K}\mathbf{\Phi}_{K,K}$$and$$\mathbf{V}_{K,K}^{- 1} = \frac{1}{\beta_{K}}\mathbf{\Phi}_{K,K}$$where **Φ**~K,K~ is the eigen-vectors and **β**~k~ is the eigen-values of the property square matrix **V**~K,K~.

Iterative solution of 2L-PCA equations {#s3_4}
--------------------------------------

In the training dataset for drug candidates the two prediction coefficients set **A**~K~ and **B**~L~ in the 2L-PCA general equation Eq.[6](#eq006){ref-type="disp-formula"} are solved in an iterative procedure \[[@R74], [@R75]\]. Firstly the initial fragment coefficients **B**^(0)^~L~ are assigned to 1 {b~*i*~=1, *i*=1,2...,L}, implying all fragments are equally important. The initial **B**^(0)^~L~ are used in the property 2D equations Eq [(9)](#eq009){ref-type="disp-formula"} and [(10)](#eq010){ref-type="disp-formula"}, thus the first solution of property coefficients **A**^(1)^~K~ is obtained by solving the eigen-equations Eq.[17](#eq017){ref-type="disp-formula"}-[20](#eq020){ref-type="disp-formula"}. Then the property coefficients **A**^(1)^~K~ are used in the fragment equations Eqs.[7](#eq007){ref-type="disp-formula"}-[8](#eq008){ref-type="disp-formula"}, and the first solution of fragment coefficients **B**^(1)^~L~ are obtained by solving eigen-equations Eq.[11](#eq011){ref-type="disp-formula"}-[14](#eq014){ref-type="disp-formula"}. In the next iterative cycle the **B**^(1)^~L~ is used to find the **A**^(2)^~K~. Above iterative procedure is repeated for *n* times, until to reaching a threshold value ε; i.e.,$$\left| {Q^{({n + 1})} - Q^{(n)}} \right| = \left| {\sqrt{\frac{1}{N}{\sum\limits_{i = 1}^{N}\left( {w_{i}^{\mathit{expt}} - w_{i}^{({n + 1})}} \right)^{2}}} - \sqrt{\frac{1}{N}{\sum\limits_{i = 1}^{N}\left( {w_{i}^{\mathit{expt}} - w_{i}^{(n)}} \right)^{2}}}} \right| \leq \varepsilon$$

The bioactivities of designed drugs and newly synthesized drug candidates are predicted using the converged coefficients $\left\{ a_{k}^{(n)} \right\}$ and $\left\{ b_{l}^{(n)} \right\}$ as given below$$w_{i}^{\text{pred}} = {\sum\limits_{l = 1}^{L}b_{l}^{(n)}}\left( {\sum\limits_{k = 1}^{K}{a_{k}^{(n)}x_{i,l,k}}} \right)$$

Illustrated in Figure [5](#F5){ref-type="fig"} is the iterative solution procedure for the 2L-PCA predictor.

![The iterative algebra solution procedure of the solution of 2L-PCA prediction model for the two sets of coefficients {*a*~*k*~^(*n*)^} and {*b*~*l*~^(*n*)^}, where *N* is the number of molecular samples, *L* is the number of fragments in molecules, *L*′ is the principal number of fragments, *K* is the number of physicochemical properties, and *K*′ is the principal number of properties](oncotarget-08-70564-g005){#F5}

Principal component analysis of properties and fragments {#s3_5}
--------------------------------------------------------

The property eigenvectors $\left\{ \varphi_{k} \right\}$ are orthogonal and normalized; i.e.,$$\varphi_{k}\quad\varphi_{j} = 0\left( {k \neq j} \right)$$and$$\varphi_{k}\quad\varphi_{k} = {\sum\limits_{j = 1}^{K}{\varphi_{j,k}^{2} = 1}}$$where the term φ^2^~*j,k*~ is the component of the *j*-th property in the *k*-th eigen-vector **φ**~***k***~. The first K′ property eigen-vectors are the principal components whose eigen-values are larger than a threshold (e.g., ε=90% or 95%); i.e.,$$\frac{\sum_{K = 1}^{K^{\prime}}\beta_{k}^{2}}{\sum_{k = 1}^{K}\beta_{k}^{2}} \geq \varepsilon$$

The total contribution γ~*j*~ of the *j*-th property to the bioactivity of molecular samples in training set is defined as the following summation,$$\gamma_{j} = {\sum\limits_{K = 1}^{K^{\prime}}{\beta_{k}\varphi_{j,k}^{2}}}$$

The property eigen-vectors $\left\{ \varphi_{k} \right\}$ span an orthogonal multiple space, in which a drug molecule P~*i*~ is a vector, and its projection *J*~*i,k*~ on the *k*-th property-eigenvector **φ**~*k*~ is calculated by$$J_{i,k} = \frac{\mathbf{f}_{i}.\phi_{k}}{\left| \mathbf{f}_{i} \right|\left| \phi_{k} \right|} = \frac{\sum_{j = 1}^{K}{f_{i,j}\varphi_{j,k}}}{\sqrt{\sum_{j = 1}^{K}f_{i,j}^{2}}\sqrt{\sum_{j = 1}^{K}\phi_{i,j}^{2}}}$$where **f**~*i*~ is the *i*-th row vector of the property matrix **F**~NK~ of Eq.[9](#eq009){ref-type="disp-formula"}. In the projection *J*~*i,k*~ of molecular sample P~*i*~ on the *k*-th property-eigenvector **j**~*k*~ the component of the *r*-th property is α~*k*~φ^2^~*r,k*~, therefore the total contribution of *r*-th property to the sample P~*i*~ is the summation of components from all principal property eigenvectors, namely$$\xi_{i,r} = {\sum\limits_{k = 1}^{K^{\prime}}{\beta_{k}J_{i,k}\varphi_{r,k}^{2}}}$$

Similarly, the fragment eigenvectors ψ~*l*~ span an L-dimensional orthogonal space. The first L′ fragment eigenvectors are the principal components. The total contribution factor λ~*j*~ of the *j*-th fragment to the bioactivity of peptide set is given by$$\lambda_{j} = {\sum\limits_{l = 1}^{L^{\prime}}{\alpha_{l}\psi_{j,l}^{2}}}$$

In the same way the projection *I*~*i,l*~ of sample P~*i*~ on the *l*-th fragment-eigenvector ψ~*l*~ can be calculated by$$I_{i,l} = \frac{\mathbf{h}_{i}.\phi_{l}}{\left| \mathbf{h}_{i} \right|\left| \phi_{l} \right|} = \frac{\sum_{j = 1}^{L}{h_{i,j}\psi_{j,l}}}{\sqrt{\sum_{j = 1}^{L}h_{i,j}^{2}}\sqrt{\sum_{j = 1}^{L}\psi_{i,j}^{2}}}$$where **h**~*i*~ is the *i*-th row vector of the fragment matrix **H**~NL~ of Eq.[7](#eq007){ref-type="disp-formula"}. In the projection *I*~*i,l*~ of molecule P~*i*~ on the *l*-th fragment-eigenvector **φ**~*l*~ the component of the *r*-th fragment is α~*l*~ψ^2^~*r,l*~, therefore the total contribution of *r*-th fragment to the sample P~*i*~ is the summation of components from all principal fragment eigenvectors; i.e.,$$\varsigma_{i,r} = {\sum\limits_{l = 1}^{L^{\prime}}{\alpha_{l}I_{i,l}\psi_{r,l}^{2}}}$$

Web-server {#s3_6}
----------

As pointed out in \[[@R76]\], user-friendly and publicly accessible web-servers represent the future direction for developing practically more useful predictors or any computational tools. Actually, user-friendly web-servers as given in a series of recent publications \[[@R23]-[@R25], [@R30], [@R32], [@R34]-[@R36], [@R69], [@R70], [@R77]-[@R91]\] will significantly enhance the impacts by attracting the broad experimental scientists \[[@R66], [@R92]\]. We will do our best to establish a web-server for 2L-PCA as soon as possible. Once it has been done, an announcement will be made thorough a publication or our webpage.

CONCLUSION {#s4}
==========

The 2L-PCA predictor proposed in this paper is a very useful tool for drug design. Its advantages can be summarized as follows. (1) With 2L-PCA, the molecular structures of drug candidates can be separated into several fragments described by physicochemical parameters of the molecular fragments, thus the small modifications on individual fragments can be clearly shown. (2) Its two prediction coefficient sets $\left\{ a_{k} \right\}$ of properties and $\left\{ b_{l} \right\}$ of fragments can be solved in an iterative procedure, which possesses self-learning ability and information feed-back function in certain degree, and hence greatly promoting the prediction power of 2L-PCA. (3) It possesses the information from both of the structures of molecular fragments and the physicochemical properties, able to significantly improve the drug candidates in both the structure and property. (4) Its elegant algebra solution procedure will be very useful for further enhancing the ability of principal component analysis (PCA).
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